Richmond, VA Clinical Trials Report — May 2026

For Richmond residents considering participation in clinical research, May 2026 brings important opportunities, particularly for those looking to join trials before their enrollment windows close. Across the city, 610 clinical trials are actively recruiting across 221 research facilities, offering a wide range of options for patients and healthy volunteers alike.

Act Now: Trials Closing Soon in Richmond

Time is of the essence for individuals interested in 33 clinical trials that are slated to conclude within the next 90 days. This urgency extends to healthy volunteers, as 2 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a valuable chance to contribute to medical advancements before their enrollment deadlines pass.

Conditions with trials nearing their closing dates include:

• Kidney transplant complications (2 trials)
• Anthracycline related cardiotoxicity in breast cancer (1 trial)
• Celiac disease (1 trial)
• BK virus infection (1 trial)
• Traumatic brain injuries (1 trial)
• Breast cancer (1 trial)
• Attention-deficit/hyperactivity disorder (1 trial)
• Cerebellum conditions (1 trial)
• Cervical dystonia (1 trial)
• Chronic granulomatous disease (CGD) (1 trial)

New Research Opportunities Emerge This Month

Richmond saw the opening of 5 new clinical trials in May 2026, a slight decrease from the 6 trials that launched in March 2026. These new studies bring fresh avenues for participation, particularly in areas of significant public health interest.

This month features 2 major Phase 3 drug trials from Novo Nordisk A/S, a leading pharmaceutical sponsor, focusing on obesity and heart failure. These large-scale studies offer participants the chance to engage with cutting-edge treatments:

• NCT07567001: "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." Sponsored by Novo Nordisk A/S, this Phase 3 study aims to enroll 5,610 participants. It will evaluate the safety and effectiveness of NNC0487-0111 in individuals with Heart Failure with preserved or mildly reduced Ejection Fraction who also have excess body weight.
• NCT07564414: "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." Also sponsored by Novo Nordisk A/S, this Phase 3 trial is designed for 2,500 participants. The study will assess the safety and efficacy of CagriSema for body weight loss in people living with obesity, regardless of whether they have type 2 diabetes.

Another notable new study is a research registry from OvationLab:

• NCT07605078: "Associations Between Household Mold Levels and Physical and Mental Health: A Mold and Mycotoxin Testing Research Registry." This study, sponsored by OvationLab, aims to enroll 2,500 participants. Its primary purpose is to explore the connections between mold exposures, identified through The Dust Test, and self-reported physical health, emotional health, and medical diagnoses.

The new trials this month are exploring a diverse range of conditions, including:

• Obesity
• Heart failure
• Bowel preparation for colonoscopy, efficacy, tolerability, and safety
• Colon cancer screening
• Detoxification
• Inflammation
• Mold illness or mold/dust allergy
• Biological aging

Of the new studies, 3 are drug trials, 2 are classified as "OTHER" research, and 1 is a dietary supplement trial.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are opportunities to contribute to research. Of the 5 new trials launched this month, 1 is actively seeking healthy volunteers. Overall, Richmond currently has 42 clinical trials recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Richmond's Leading Research Hubs

Richmond is home to several prominent research institutions that consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Virginia Commonwealth University (149 trials)
• VCU Massey Comprehensive Cancer Center (121 trials)
• VCU Massey Cancer Center at Stony Point (62 trials)
• Virginia Cancer Institute (26 trials)
• Bon Secours Saint Mary's Hospital (25 trials)
• Bon Secours Cancer Institute at Reynolds Crossing (23 trials)
• Research Site (23 trials)
• Bon Secours Richmond Community Hospital (14 trials)
• Clinical Research Partners, LLC (11 trials)
• VCU Medical Center (11 trials)
• Virginia Commonwealth University Massey Cancer Center (11 trials)
• Richmond VA Medical Center (9 trials)

These institutions, particularly those within the Virginia Commonwealth University system and the Bon Secours network, offer a broad spectrum of research, with a strong focus on oncology at the various Massey Cancer Center locations and the Virginia Cancer Institute.

Expanding Your Search: Nearby Virginia Cities

While Richmond offers a substantial array of clinical trial opportunities, individuals may also find options in nearby communities within Virginia. Cities with active trials include:

• Fairfax (6 trials)
• Charlottesville (4 trials)
• Norfolk (3 trials)
• Newport News (2 trials)
• Gordonsville (1 trial)
• Leesburg (1 trial)
• Manassas (1 trial)
• Roanoke (1 trial)

Who Can Participate?

Participation in clinical trials is open to a diverse range of individuals. Of the 5 new trials launched this month, 1 includes children, and all 5 include older adults, ensuring that various age groups have opportunities to contribute to medical science. No new trials this month are exclusively for females or males.

Industry sponsors like Novo Nordisk A/S and OvationLab are driving significant research efforts in Richmond, alongside network and federally funded studies. This mix of sponsorship ensures a broad and impactful research landscape.

As we move through May, Richmond's active research community continues to advance medical understanding, offering diverse opportunities for individuals to contribute to the future of healthcare.